The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Lithobid slow-release tablets in a 300mg dosage have been
approved for the treatment of manic depression. Lithobid provides
twice-daily dosing as opposed to several times a day for
immediate-release preparations; Lithobid's slow-release
formulation helps to minimize variations in lithium concentrations
as compared with immediate-release preparations.
The lifetime risk of manic depression is 1.2%, with an annual
incidence of 9-15 new cases per 100,000 per year for men, and seven
to 30 new cases per 100,000 per year for women. Studies have shown
that an estimated 20 % of all cases of major mood disorders result
from manic depression.
Manic episodes are distinct periods in which one's mood
changes from its normal state to an abnormally and persistently
elevated, expansive, or irritable mood. The associated symptoms
include inflated self-esteem or grandiosity, feeling of elation,
euphoria, decreased need for sleep, pressure of speech, flight of
ideas, distractibility, aggressiveness, and possible hostility.
Lithium has been used to treat manic depression for more than 20
years and is most likely to be effective in subjects with pure
manic symptomatology (elation and grandiosity). Response rates in
these subjects may be as high as 90%.